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Abstract
Introduction: Breast cancer is a complex and heterogeneous disease at the molecular level. Evolution is difficult to
predict according to classical histoclinical prognostic factors. Different studies highlight the importance of large-scale
molecular expression analyses to improve taxonomy of breast cancer and prognostic classification. Identification of new
molecular markers that refine this taxonomy and improve patient management is a priority in the field of breast cancer
research.
Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4
as a new histological and serological tumor associated marker for breast carcinoma.
Methods: Expression of Nectin-4 protein was measured on a panel of 78 primary cells and cell lines from different
origins and 57 breast tumors by FACS analysis and immunohistochemistry (IHC), respectively. mRNA expression was
measured by quantitative PCR.
Serum Nectin-4 was detected by ELISA and compared with CEA and CA15.3 markers, on panels of 45 sera from healthy
donors, 53 sera from patients with non-metastatic breast carcinoma (MBC) at diagnosis, and 182 sera from patients with
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standard Chi-2 test.
Results: Nectin-4 was not detected in normal breast epithelium. By contrast, Nectin-4 was expressed in 61% of ductal
breast carcinoma vs 6% in lobular type. Expression of Nectin-4 strongly correlated with the basal-like markers EGFR,
P53, and P-cadherin, and negatively correlated with the luminal-like markers ER, PR and GATA3. All but one ER/PR-
negative tumors expressed Nectin-4. The detection of Nectin-4 in serum improves the follow-up of patients with MBC:
the association CEA/CA15.3/Nectin-4 allowed to monitor 74% of these patients compared to 67% with the association
CEA/CA15.3. Serum Nectin-4 is a marker of disease progression, and levels correlate with the number of metastases (P
= 0.038). Serum Nectin-4 is also a marker of therapeutic efficiency and correlates, in 90% of cases, with clinical evolution.
Conclusion: Nectin-4 is a new tumor-associated antigen for breast carcinoma. Nectin-4 is a new bio-marker whose use
could help refine breast cancer taxonomy and improve patients' follow-up. Nectin-4 emerges as a potential target for
breast cancer immunotherapy.
Introduction
Breast cancer is the most common malignancy in women
and will affect around one in 10 women during their life-
time. Breast cancer is a heterogeneous disease at the
molecular level and treatment is efficient in only 70% of
cases [1]. Identification of new molecular tumor associ-
ated biomarkers is one the most important current chal-
lenge [2]. Tumor associated molecular markers can be
useful to improve the detection, taxonomy, diagnosis,
prognosis, follow-up, and therapy of breast cancer.
Individual molecular markers and patterns of markers
subdivide traditional breast cancer classes into subsets
that behave as useful taxonomic and prognosis entities.
ERBB2 is the prototypic individual marker: it is a marker
of adverse prognosis, and the serum detection of a soluble
form is used in the follow-up of breast cancer patients. It
is also a therapeutic target. Beside ERBB2 overexpressing
breast tumors, four other subtypes (luminal A, luminal B,
basal and normal-like) have been described according to
patterns of marker expression using DNA and tissue
microarrays [3-6]. Luminal-A and basal breast cancers cor-
respond to two very distinct epithelial subtypes. They
show different clinical course and response to therapy [4-
8]. However, this classification lacks precision as judged
by the adverse evolution of many patients with apparent
good prognosis and vice versa. Thus, there is a need to
define new markers to refine histoclinical and molecular
classifications and improve breast cancer management.
We have recently characterized a new family of cell adhe-
sion molecules homologous to PVR/CD155 (the PolioVi-
rus Receptor) named Nectins [9-12]. Nectins are members
of the immunoglobulin superfamily (IgSF) and are com-
ponents of E-cadherin-based adherens junctions in epi-
thelial cells. Four Nectins have been described so far. They
are structurally related and exhibit three conserved immu-
noglobulin-like domains (V, C, C) in their extracellular
regions. Nectins and E-cadherin are linked to F-actin
through AF-6/Afadin and Catenins, respectively [13]. The
Nectin/Afadin and E-cadherin/Catenins systems interact
with each other through Afadin and α-catenin. Nectins
and Afadin have been involved in tumor biology. i) PVR
and Nectin-2 have been described as tumor antigens and
are molecular targets of NK cells through the interaction
with the DNAM-1/CD226 molecule [14], ii) PVR is over-
expressed in tumors of hematopoietic, neuronal and epi-
thelial origins [15-17], iii) Nectin-1 is overexpressed is
squamous carcinomas [18], and iv) Afadin is ubiquitously
expressed in epithelia, and its loss has been associated
with poor outcome in breast carcinoma [19].
All Nectins except Nectin-4 are expressed in epithelial,
endothelial, hematopoietic and neuronal cells in adult tis-
sues [12]. Nectin-4 is mainly expressed during embryo-
genesis but is not detected in normal adult tissues nor in
serum.
In the present study, we show that Nectin-4 is a new
tumor-associated antigen and a reliable marker for breast
carcinoma. Nectin-4 is indeed not detected in normal
breast epithelial cells, and highly expressed both in tumor
cell lines and tumors from breast origin. Nectin-4 expres-
sion profile correlates with the expression of markers that
define the basal subtype in breast tumors. Finally, Nectin-
4 is shed from the tumor cell surface and represents a sen-
sitive, reliable, and complementary serum marker for the
follow-up of patients with metastatic breast carcinoma.
Materials and methods
Patients and histological samples
Liquid nitrogen flash-frozen breast cancer samples were
randomly selected from consecutive series of more than
650 ductal and 110 lobular breast carcinoma samples. A
panel of 57 tumor samples at the time of diagnosis and
prior any adjuvant therapy was obtained from women
treated at the Institut Paoli-Calmettes, Marseille, France.
Consecutive series of 26 ductal and 31 lobular carcinomaPage 2 of 16
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histological type. Tumors were classified according to the
WHO classification. The histoprognostic grade used was
the modified Scarf Bloom Richardson (SBR) grading for
invasive lesions. Five normal breast samples were
obtained from healthy women who had undergone
reductive mammary surgery.
Patient serum selection
Several panels were selected: Series of 45 sera from healthy
female donors, without evidence of breast cancer; 53 sera
from patients with non MBC at diagnosis who were not
receiving any therapy; 182 sera from patients with MBC
(81% ductal, 19% lobular): 70 sera corresponding to syn-
chronous MBC patients and 112 sera to metachronous
MBC patients, 64 of which with samples collected before
and after specific anticancer treatment. For each panel,
selection was random. Analyses of other specific biomar-
kers, CEA and CA15.3 were done on these sera.
This study was approved and executed in compliance with
our Institutional Review Board.
Cells and culture conditions
Human leukocytes were purified from healthy donors
using Ficoll separation. Human umbilical vein endothe-
lial cells (HUVEC) were isolated and cultivated as previ-
ously described [20]. CD34 positive cells were purified
with magneted activated cell sorter (MACS) as already
reported [21]. Hematopoietic cell lines were cultivated in
RPMI medium supplemented with 10% foetal calf serum.
The 31 breast tumor cell lines have been previously
described [22]. The bladder tumor cell lines were kindly
provided by Dr. F. Radvanyi (Institut Curie, Paris, France).
Ovarian O114, O151 and O170 cell lines were kindly pro-
vided by Pr V. Catros (CHU de Rennes, France). Ovarian
TOV-21G, TOV-112D and OV-90 were a gift from Pr. Mes-
Masson (Institut du Cancer de Montréal, Canada) [23].
IGR-OV1 was from Institut Gustave-Roussy, Paris, France.
The other cell lines were from ATCC (Manassas, VA, USA).
All cell lines were grown according to the recommenda-
tions of the supplier, in an air – 5% CO2 atmosphere at
constant humidity.
RNA extraction
Total RNA was extracted from frozen cell lines as previ-
ously described [24]. RNA integrity was controlled by
electrophoresis on agarose gels and by Agilent micro-anal-
ysis (Agilent Bioanalyzer, Palo Alto, USA).
Quantitative PCR
Complementary DNA (cDNA) was synthesized from 2 μg
total RNA using SuperScript™ III Reverse Transcriptase kit
(Invitrogen, France). Expression of Nectin4 and GUSB
(located at 7q21.11 and used for normalisation of expres-
sion data) was measured using the LightCycler®FastStart
DNA MasterPLUS SYBR Green I kit in the Light Cycler® 2.0
instrument (Roche, Germany), as recommended by the
supplier.
The expression of Nectin4 and GUSB (located at 7q21.11
and used for normalisation of expression data) was meas-
ured using the LightCycler®FastStart DNA MasterPLUS SYBR
Green I kit in the Light Cycler® 2.0 instrument (Roche,
Germany), as recommended by the supplier.
Relative quantitative analysis of the expression of Nectin 4
gene was performed with serially diluted samples of EcoRI
linearised plasmid containing the ORF cloned in the
pFLAG-CMV25 vector (Sigma). Nectin-4 primers were
defined using the "primer3" algorithm. Two primers were
selected: huN4S: CAAAATCTGTGGCACATTGG and
huN4AS: GCTGACATGGCAGACGTAGA leading to an
amplified product of 189 bp. For the relative quantitative
analysis of GUSB gene, serially diluted samples were pur-
chased from Ipsogen (Marseille, France).
The relative expression level of Nectin4 in each sample was
calculated by normalizing the corresponding expression
with GUSB expression values.
Antibodies for Nectin-4
Anti-Nectin-4 monoclonal antibodies (mAbs) were
obtained after successive intraperitoneal injections of
BALB/c mice with 20 μg of human recombinant soluble
Nectin-4 (N4VCC)-Fc [25]. Two hundred clones were
tested for differential reactivity to COS cells and COS cells
transiently expressing human Nectin-4. MAbs were then
tested for cell surface detection of Nectin-4 by FACS anal-
ysis and for their ability to react with soluble recombinant
Nectin-4, N4VCC-Fc and N4V-Fc (Nectin-4 deleted from
its 2 IgC domains) by ELISA (see below). Two clones were
thus selected: N4.61 clone is specific of the IgV domain
and N4.40 clone is specific of one of the two IgC domains
[25]. These mAbs did not recognize Nectin-1, Nectin-2,
Nectin-3 nor PVR (data not shown).
Cell surface expression analysis of Nectin-4
2 × 105 cells were incubated for 60 min at +4°C with 10
μg/ml of either N4.40 or N4.61 mAbs, washed, and then
revealed by incubation for 45 min at +4°C with a phyco-
erythrin labelled goat anti-mouse antibody (Immu-
notech, France). Samples were processed by FACS
analysis. Mean Fluorescence Intensity (MFI) value of each
sample were measured and normalized by the MFI value
of isotypic control.
Selection of markers
Proteins were selected according to i) their previously
described role as breast cancer taxonomic immunohisto-Page 3 of 16
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ERBB2, EGFR, P53, BCL2, GATA3, P-cadherin [22,26,27],
and ii) their functional relevance to Nectin biology, i.e., E-
cadherin, β-catenin and AF-6/afadin [11-13]. Characteris-
tics of the antibodies and experimental conditions were
previously described [22].
Immunohistochemical analysis (IHC)
For Nectin-4, IHC was carried on 5 μm sections from fro-
zen tissue. Sections were fixed in acetone for 10 min, air-
dried for 10 min and rehydrated in TBST (Dako, Coppen-
hagen, Denmark). Staining was done at room tempera-
ture and DAKO EnVision™ System was used to reveal the
staining. Slides were first incubated with the primary anti-
body N4.61 or N4.40 (0.5 μg/ml) for 30 min. After
washes in TBST, slides were incubated with secondary
antibodies (anti-mouse) conjugated with alkaline phos-
phatase for 30 min. Fast Red substrate-chromogen solu-
tion was prepared and used as dye. Slides were counter-
stained with haematoxylin, and mounted on slide using
Aquatex (Merck, Darmstadt, Germany).
For the other markers, IHC was carried on tissue microar-
rays prepared as previously described. They were depar-
affinized in Histolemon (Carlo Erba Reagenti, Rodano,
Italia) and rehydrated in graded alcohol. Antigen
enhancement was done by incubating the sections in cit-
rate buffer pH 6 (Dako, Coppenhagen, Denmark) as rec-
ommended. Slides were then transferred to a Dako
autostainer. Staining was done at room temperature as
follows. After washes in phosphate buffer, followed by
quenching of endogenous peroxidase activity by treat-
ment with 0.1% H2O2, slides were first incubated with
blocking serum (Dako) for 10 min and then with the pri-
mary antibody for one hour. After washes, slides were
incubated with biotinylated secondary antibody for 20
min followed by streptavidin-conjugated peroxidase
(Dako LSABR2 kit). Diaminobenzidine was used as the
chromogene. Slides were counterstained with haematoxy-
lin, and mounted on slides using Aquatex (Merck, Darm-
stadt, Germany) mounting solution. Slides were
evaluated under a light microscope. Immunoreactivities
were classified by estimating the quick score (Q) as previ-
ously described [22]. ERBB2 status was calculated with the
Dako scale (Herceptest™ kit scoring guidelines). Quick
score allowed the separation of tumors into two or three
classes. Homogeneous classes were defined by grouping
samples with an equivalent staining level according to the
distribution curves as described. Negative and positive
classes were defined for Afadin, α and β catenins. EGFR,
GATA3, P53, P-cadherin, and PR were defined with a pos-
itivity cut-off value of Q = 1. Positivity cut-off value for
MIB1/Ki67 and Nectin-4 was Q = 20. Three classes were
defined (negative (Q = 0), moderate (0 < Q ≤ 100) and
strong staining (100 < Q ≤ 300) for E-cadherin and ER. For
ERBB2 three classes (0/1+, 2+, 3+) were defined according
to the Dako scale. Corresponding antibodies have been
previously described [26]. Unsupervised hierarchical clus-
tering was used to investigate relations between samples
and between proteins as previously described [22].
Statistical methods
Distribution of histological/serological molecular mark-
ers and histoclinical parameters were compared using the
standard Chi-2 test.
ELISA
Nectin-4 ELISA has been previously described [28].
Briefly, a sandwich enzyme-linked immunosorbent assay
(ELISA) was used to detect soluble Nectin-4 in patients'
sera. Ninety-six-well trays were coated with N4.40 at 10
μg/ml. After saturation of wells with phosphate-buffer-
saline containing 1% bovine serum albumin (PBS-
1%BSA), 100 μl of culture medium or serum was incu-
bated for 12 h at 4°C, then with 2.5 μg/ml biotinylated
mAb N4.61 for 2 h at 37°C. Streptavidin-peroxidase (2
μg/ml) in PBS-1%BSA was incubated for 1 h at 37°C. One
hundred μl of peroxidase substrate was added (One Step
ABTS, Pierce) and optical density was read at 405 nm.
Three washing steps were performed between each incu-
bation with 100 μl PBS containing 0.5% Tween 20, except
for the last step (5 wash steps). Duplicates were analyzed
and mean values were calculated. For each determination,
threshold value was defined by the mean level value of 10
normal sera and was generally below 30 pM. Serum above
the threshold values (>30 pM), were considered as posi-
tive. Nectin-4 concentration in sera was calculated using
serial dilutions of soluble recombinant N4VCC-Fc (con-
centrations ranging from 1 × 10-9 M to 7.5 × 10-12 M). This
ELISA does not detect soluble Nectin-1, -2, -3, and PVR-Fc
used at the same concentrations. Sensitivity of the test is
7.5 pM. Measurement is linear up to 10-9M.
Receiving Operator Characteristic (ROC) analysis
To determine the accuracy of a diagnosis approach using
CEA, CA15.3 and Nectin-4 markers, receiver operating
characteristic (ROC) curves were produced for the four
following associations: CEA+CA15.3+Nectin-4,
CA15.3+N4, CEA+N4, CEA+CA15.3. A series of 182 sera
of MBC patients were considered for this study. Sensitiv-
ity, specificity and areas under ROC curves were calculated
in each case.
Results
Nectin-4 is prominently expressed in breast tumor cell lines
We previously cloned human and murine Nectin-4.
Northern blot analyses showed that Nectin-4 is expressed
in mouse embryo from day 11 d.p.c. Expression of Nectin-
4 differs between mouse and human adult tissues.
Whereas Nectin-4 expression was detected in brain, lung,Page 4 of 16
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slightly in trachea among 23 human tissues tested [12].
To extend this study, we analyzed the expression of Nec-
tin-4 in a panel of primary cells and tumor cells from dif-
ferent origins (Fig. 1A) using two monoclonal antibodies
(mAbs) (N4.40 and N4.61) [25,28] and FACS analysis.
Nectin-4 was not expressed in normal cells, including
endothelial (ECRF-24, HUVEC, HbMEC, Eahy926), epi-
thelial (HME-1), and hematopoietic cells (bone marrow
progenitors, monocytes, PMN, T and B lymphocytes, mast
cells). Expression of Nectin-4 in tumor cell lines varied
according to the origin of the tumor: No expression was
detected in leukemic cells. Nectin-4 was expressed in one
of four cell lines derived from prostate (LnCaP) and blad-
der (RT112) carcinomas. Half of ovarian tumor cell lines
expressed Nectin-4. Nectin-4 was expressed in the epider-
moid carcinoma cell line A431 and the choriocarcinoma
cell line BeWo. Nectin-4 expression was detected at vari-
ous levels in 68% of breast cell lines (23/34). No or mod-
erate expression was detected in non-cancerous cell lines
(HME-1, MCF-10F, MCF-10A and 184B5). Nectin-4
expression pattern is usually homogenous as exemplified
in Fig. 1B. Even though the characterization and specifi-
city of N4.40 and N4.61 mAbs have already been
reported, quantification of Nectin-4 specific transcripts
was undertaken by quantitative PCR and compared to cell
surface expression. The results show a correlation (R2 =
0.6145) between transcript and protein levels and streng-
hten the accuracy and reliability of the mAbs for the quan-
tification of Nectin-4 expression. These data demonstrate
that Nectin-4 is not expressed in normal cells and that
Nectin-4 is prominently expressed in ovarian and above
all, in breast tumor cell lines.
Nectin-4 is prominently expressed in ductal breast 
carcinoma
We then studied Nectin-4 expression in normal breast epi-
thelium and breast carcinoma. Ductal and lobular carci-
noma account for around 80% and 15% of breast cancers,
respectively. For each of these histologic types, specimens
were randomly selected from our resources and analyzed
by IHC for Nectin-4 expression.
Nectin-4 was not detected in sections of normal breast tis-
sues, including luminal, myoepithelial, stromal and
endothelial cells (Fig. 2A). Expression was detected in
62% of ductal type and 6% of lobular type carcinoma
strengthening our results obtained with cell lines. Nectin-
4 expression thus strongly correlates with histological type
(see Table 1). As examplified in Fig. 2B, Nectin-4 was
expressed both in non-invasive (white arrow) and inva-
sive (black arrow) tumors. Detailed analysis showed that
Nectin-4 was exclusively expressed in carcinoma cells and
absent from myoepithelial and stromal cells (data not
shown). IHC showed a cytoplasmic and discrete mem-
brane localization of Nectin-4 (Fig. 2A and 2B). Immun-
ofluorescence studies confirmed IHC and revealed a
cytoplasmic expression of Nectin-4 and a clear localiza-
tion at intercellular junctions between carcinoma cells
(Fig. 2C, white arrow). These data show that Nectin-4 is a
new marker for breast carcinoma and that its expression
strongly correlates with the ductal histological type. More-
over, Nectin-4 expression was not detected in normal
breast epithelium suggesting that it can represent a new
tumor-associated antigen.
Nectin-4 expression correlates with basal breast markers
A molecular taxonomy of breast cancers has been pro-
posed that may be related to the differentiation model of
breast epithelium. This taxonomy has been well estab-
lished by gene expression profiling studies [3,4,6]. Studies
attempting to define breast cancer subtypes by protein
expression profiling have also been reported [22,26,27].
Although very informative, the latter approach needs the
characterization of new reliable immunohistochemical
markers.
Expression of Nectin-4 was compared with the expression
of protein markers on 52 early stage breast tumors. Pro-
teins were selected to identify either basal (EGFR, P53 and
P-cadherin) or luminal subtype (ER, PR, GATA3)
[26,29,30]. In addition, expression of ERBB2 and of the
proliferation marker Ki67 were also analyzed. Expression
of E-cadherin, β-catenin and AF6/Afadin, functionally
associated with Nectin physiology, were also tested.
The overall expression patterns for the 52 samples were
analyzed with hierarchical clustering and displayed in a
color-coded matrix (Fig. 3). Clustering ordered proteins
on the horizontal axis, and tumor samples on the vertical
axis on the basis of similarity of their expression profiles.
This similarity is shown as a dendrogram in which the
length of the branches between two elements reflects their
degree of relatedness. A color scale indicates the intensity
of protein expression from red for strong staining to green
for negative staining. Nectin-4 was identified in a cluster
of proteins with EGFR, P53 and P-cadherin (Fig. 3, orange
cluster and Table 1). As seen in Table 1, there was strong
correlation between Nectin-4 and expression of these
markers. Nectin-4 expression was negatively correlated
with expression of proteins that define the luminal cluster
(ER, PR, GATA3) (Fig. 3, blue cluster and Table 1). A sig-
nificant, although lower correlation, was noted with
ERBB2, Ki67, E-cadherin and β-catenin. More generally,
Nectin-4 expression was found in 7 out of 8 of ER/PR-neg-
ative tumors. No correlation was noted with AF6/Afadin.
Altogether, our data described Nectin-4 as a new protein
marker for ductal breast carcinoma. Nectin-4 expressionPage 5 of 16
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Analysis of Nectin-4 expression in normal and tumor cellsFigure 1
Analysis of Nectin-4 expression in normal and tumor cells. A: Cell surface expression of Nectin-4 was assessed by 
FACS analysis using the N4.61 mAb. The level of cell surface expressed Nectin-4 (L) was calculated in arbitrary units based on 
fluorescence intensity: L = MFI N4.61/MFI control IgG1. Similar results were obtained with the N4.40 mAb. L = 1 corresponds 
to negative cell lines, 2 < L < 15: low expression, 16 < L < 50: intermediate expression, L > 50 high expression. These results 
are representative of at least three independant experiments. *, non cancerous breast cell lines. B: Nectin-4 expression level 
on breast tumor cell lines was monitored by FACS analysis using the anti-Nectin-4 N4.61 mAb (black line) and compared with 
a mouse irrelevant IgG1 (gray line). Examples of a negative cell line (MDA-MB-231) and two intermediate expressing cell lines 
(T47D and MCF-7). C: Correlation between Nectin-4 cell surface expression and Nectin-4 transcriptional expression. Quanti-
tative PCR was performed on 17 breast tumor cell lines. Values were calculated as described in material and methods. The 
results are representative of at least two experiments.
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basal-like subtype.
Nectin-4 is a new serological marker for metastatic breast 
carcinoma
We recently showed that transmembrane Nectin-4 is shed
from cell surface, leading to the release of the ectodomain
in the culture supernatant. This soluble form of 43.5 kDa
comprises the three Ig domains of Nectin-4 (V, C, C). The
endoprotease TACE/ADAM-17 cleaves Nectin-4 close to
the plasma membrane [28]. Circulating forms of cell
adhesion molecules have been reported in different dis-
eases, especially in cancer. However, only two serum
markers (CEA and CA15.3) are commonly used to search
for MBC but they fail to detect metastasis in all patients
and false positivity has been reported.
We thus looked for the presence of a Nectin-4 circulating
form in the sera of patients with breast carcinoma. This
analysis was performed by ELISA using the N4.40 and the
N4.61 mAbs.
Table 1: Correlation between histoclinical markers and Nectin-4 expression determined by IHC
Characteristics N° of patients (%) P-value
Nectin4 negative (N=39) 68.4% Nectin4 positive (N=18) 31.6%
Age <50 5 (14) 4 (29) NS
>50 31 (86) 10 (71)
Histological type Ductal 10 (26) 16 (89) <0.0001
Lobular 29 (74) 2 (11)
SBR grade I 9 (25) 3 (21) NS
II 17 (47) 6 (43)
III 10 (28) 5 (36)
Axillary lymph node st. Negative 19 (53) 6 (43) NS
Positive 17 (47) 8 (57)
EGFR Negative 31 (94) 7 (54) 0.0012
Positive 2 (6) 6 (46)
ERBB2 status 0-1 34 (94) 10 (71) 0.0245
2-3 2 (6) 4 (29)
Ki67 Negative 23 (79) 7 (50) 0.05
Positive 6 (21) 7 (50)
P53 status Negative 33 (97) 7 (50) <0.0001
Positive 1 (3) 7 (50)
P-cadherin Negative 25 (74) 4 (29) 0.0029
Positive 9 (26) 11 (71)
BCL2 Negative 2 (6) 6 (43) 0.0025*
Positive 30 (94) 8 (57)
Estrogen receptor st. Negative 0 (0) 7 (50) <0.0001*
Positive 37 (100) 7 (50)
GATA3 Negative 3 (9) 6 (60) 0.0004*
Positive 31 (91) 4 (40)
Progesterone receptor st. Negative 8 (24) 8 (57) 0.0247*
Positive 26 (76) 6 (43)
* Negative correlation with Nectin-4 expressionPage 7 of 16
(page number not for citation purposes)
BMC Cancer 2007, 7:73 http://www.biomedcentral.com/1471-2407/7/73
Page 8 of 16
(page number not for citation purposes)
Nectin-4 expression in breast carcinomaFigure 2
Nectin-4 expression in breast carcinoma. A: Normal breast epithelium does not express Nectin-4. No expression was 
detected in luminal, myoepithelial and stromal cells. Nectin-4 expression was found prominently in ductal carcinoma. Bar 50 
μm. Magnification: × 200. B: Both invasive (black arrow) and in situ (white arrow) components of ductal carcinoma are immu-
nostained by Nectin-4. C: Immunofluorescence analysis revealed that Nectin-4 expression is cytoplasmic (arrowhead) and 
junctional (arrow). Similar results were obtained with both mAbs Magnification: × 640.
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BMC Cancer 2007, 7:73 http://www.biomedcentral.com/1471-2407/7/73First, we confirmed the presence of soluble Nectin-4 in the
culture supernatants of Nectin-4 positive cell lines (e.g.
T47D, MCF-7, MDA-MB-175) and the absence of this sol-
uble form in the culture supernatants of Nectin-4 negative
cell lines (MDA-MB-231 and MDA-MB-134) (data not
shown). Second, we found that the soluble form of Nec-
tin-4 was undetectable in 44 of 45 normal sera (Fig. 4A).
Third, we searched for soluble Nectin-4 in 53 sera of
patients with non-MBC at diagnosis. Two and three
patients were positive for CEA and CA15.3 markers,
respectively. Five sera presented Nectin-4 levels above the
threshold and among them, one serum was also found
positive for CEA and CA15.3 markers (Fig. 4A).
We extended the analysis to a panel of 182 sera of patients
with MBC and compared the results with the levels of CEA
and CA15.3 markers. As shown in Fig. 4B (black bars), cir-
culating forms of Nectin-4 were detected at various levels
(up to 1000 pM (125 ng/ml), data not shown), in 38% of
tested sera (n = 182). In these same samples, CEA and
CA15.3 markers were detected in 53% and 50% of sera,
respectively. Interestingly, whereas the combination of
the two latter markers reaches 67% detection, the associa-
tion of CEA, CA15.3 and Nectin-4 allowed 74% detection
(Fig. 4B). The increase in sensitivity, assessed by ROC
curves, is concomitant with a moderate loss of specificity
(from 0.92 to 0.84) (Fig. 4C). Sensitivity and specificity
for CEA+Nectin-4 and CA15.3+Nectin-4 were similar to
CEA+CA15.3.
Analysis was carried out in the two groups of patients with
MBC: patients with synchronous MBC (Fig. 4B, grey bars)
or with metachronous MBC (Fig. 4B, white bars). A higher
percentage of positive patients was detected for serum
Nectin-4 (and also for CEA and CA15.3) in the synchro-
nous MBC group. These data probably highlight the dif-
ferent clinical evolution of these two groups, i.e., a rapid
evolution and adverse prognosis of synchronous MBC
compared to metachronous MBC.
Our data thus show that Nectin-4 is new reliable serum
marker for patients with MBC and can improve patient
follow-up.
Serum Nectin-4 is a marker of disease progression and 
therapeutic efficiency
CEA and CA15.3 markers are classically used to follow the
evolution of patients after first remission [31]. The main
interest is the possibility to anticipate the clinically
observable recurrence. We tested whether detection of sol-
uble Nectin-4 may be used to monitor breast cancer pro-
gression. We therefore selected patients presenting
increased levels of CEA or CA15.3 during disease progres-
sion. As examplified in Fig. 5, high serum levels of Nectin-
4 (198 pM) and CA15.3 (151 U/ml) were detected in a
Nectin-4 expression correlates with basal-like breast mark-ersFigure 3
Nectin-4 expression correlates with basal-like breast 
markers. Graphical representation of hierarchical clustering 
results based on expression profiles of 9 proteins in 52 early 
breast cancer samples measured by immunohistochemistry. 
Rows: proteins; columns: samples. Protein expression scores 
are depicted according to a color scale: red, positive staining; 
green, negative staining; grey, missing data. Dendrograms 
represent overall similarities in protein expression profiles. 
Two clusters of proteins are described. A group of proteins, 
including Nectin-4, which present high expression profile 
similarities with basal breast markers. A group of proteins, 
including luminal markers, which negatively correlate with 
Nectin-4 expression and basal-like markers.
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metastasis 32 months after diagnosis (gray bars). This
patient developed cerebral metastases 39 months after
diagnosis (black bars). Whereas CA15.3 levels slightly
increased (151 to 164 U/ml), circulating Nectin-4 levels
increased two-fold (198 to 402 pM) (16 fold from level at
diagnosis). CEA levels were under the threshold value for
this patient. These results indicate that Nectin-4 represents
a valuable marker for evaluate disease progression. To
strengthen this observation, we analyzed the correlation
between Nectin-4 levels and the metastatic status of
patients based on the clinical detection at diagnosis of
either a unique or multiple metastatic localizations. We
found that the detection of serum Nectin-4 at diagnosis,
correlates with the presence of multiple metastasis in the
group of patients with synchronous MBC (P = 0.038)
(Table 2), and metachronous MBC (P = 0.014) (data not
shown). Even though CEA and CA15.3 can serve as dis-
ease progression markers, we found no significant correla-
tion with the metastasis clinical status (Table 2 and data
not shown). No correlation was found between serum
Nectin-4 and tumor size, SBR grade, axillary lymph node
or ER/PR status (data not shown). These data strongly
associate the presence of Nectin-4 in sera to disease pro-
gression and to the metastatic status of patients.
Markers can also be used to measure therapeutic efficiency
after treatment of the metastatic disease. We retrospec-
tively analyzed the presence of Nectin-4, CEA and CA15.3
in the sera of 64 patients with metachronous MBC at the
time of the metastatic diagnosis and after treatment.
Delays between two blood samplings varied from one to
nine months. Six groups were defined according to the
combination of markers found positive and the clinical
outcome (Fig. 6). Groups I and II (patients 1 to 11) corre-
spond to patients with detectable amount of the three
markers in their serum. Patients 1 to 8 showed a decrease
concomitant with a clinical response in seven cases and a
stable disease in one case; patients 9 to 11 showed an
increase concomitant with disease progression. Group III
included two patients in progression (P12 and P13)
where Nectin-4 and CA15.3 levels slightly decreased (see
supplementary data). Groups IV, V and VI (patients P14 to
P22) corresponded to groups in which Nectin-4 was
detected in patients positive for either CEA or CA15.3 or
negative for both markers. Nectin-4 levels followed clini-
cal outcome in 90% of cases (20/22).
Discussion
Nectin-4 as a potential basal marker in ductal breast 
carcinomas
The emerging molecular classification of breast cancer is
based on data obtained from gene and protein expression
profilings. Transcriptome analysis using DNA arrays has
divided breast tumors into five subtypes [3,4]. This sub-
typing contributes to the understanding of the molecular
complexity of breast tumors but is difficult to adapt to
routine use. Proteome analyzes, e.g. using IHC, has also
helped in defining molecular and prognostic signatures of
breast cancer and may be easier to use in a clinical setting
[22]. Thus, defining new protein markers that help detect-
ing and classifying breast cancer is a priority.
We identified Nectin-4 as a new breast tumor marker.
Nectin-4, non expressed in normal cells, is prominently
expressed in breast carcinoma cell lines and in breast
tumor samples. We found that Nectin-4 expression is
associated with markers that define the basal-like subtype
of breast cancer. Recently, a molecular classification of
breast tumor cell lines has been reported. Among this clas-
sification, we found that Nectin-4 is mainly expressed in
tumor cell lines with a luminal-like phenotype (BT-483,
ZR-75-30, SUM-185, SUM-52, SK-BR-3, MDA-MB-453,
HCC1500, ZR-75-1, BT-474, UACC-812, T47D, MCF-7)
and absent or weakly expressed in tumor cell lines with a
basal-like phenotype (HCC1937, SUM-149, MDA-MB-
175, 184B5, MCF-10A, HCC38, BT20, SK-BR-7, MDA-
MB-231, MDA-MB-157, Hs578T, BRCa-MZ-01) [26].
These results have been obtained using two different
mAbs and validated at the mRNA level. To further docu-
ment this intriguing point, we looked for other genes with
inverse correlation between tumors and cell lines for
basal/luminal subtypes, in our gene expression profiling
data. Among 47.000 transcripts and variants present on
the array, we found 11 genes presenting an inverse signa-
ture: the breast stem cell marker CD24, the junctional
adhesion molecule JAM-A and the EPHB3 receptor. Inter-
estingly, we found three reports that define CD24 as a
luminal-like protein in breast tumor cell lines [32], as a
marker whose expression is close to the basal-like gene
cluster [33] or whose expression falls into the ER/PR-neg-
ative cluster [34], in breast tumors. Thus, CD24 expres-
sion does not correlate with the luminal subtype in
tumors but rather with markers associated with the basal
subtype. Even though these data unambiguously confirm
ours, the significance of this set of genes is not clear and
will need further investigation. They may be genes partic-
ularly involved in stroma-epithelium interactions.
Nectins belong to a family of cell adhesion molecules that
regulate the formation and maintenance of adherens
junctions in epithelial cells through the AF-6/afadin scaf-
fold molecule [11,12,35]. The Nectin/Afadin complex
indirectly interacts with the E-cadherin/β-catenin com-
plex. Loss of Afadin is associated with poor outcome for
patients with breast carcinoma [19]. Nectin-4 interacts
with Afadin but no significant correlation has been found
between the expression of these two proteins in breast car-
cinoma (P = 0.706) [12]. By contrast, we found a correla-
tion between E-cadherin (P = 0.0113) and β-catenin (P =Page 10 of 16
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Detection of Nectin-4 in serum from patients with MBCFigure 4
Detection of Nectin-4 in serum from patients with MBC. Serum Nectin-4 was detected by ELISA using a pair of anti-
Nectin-4 mAbs. A: Percentage of Nectin-4 positive sera in healthy donors (n = 45), and in patients with non-metastatic breast 
tumors compared with CEA and CA15.3 levels (n = 53). B: Percentage of sera positive for Nectin-4, CEA and CA15.3 and 
combinations of markers. The association of Nectin-4 with CEA and CA15.3 increases the percentage of patients detected. 
White bars; patients with metachronous MBC. Grey bars; patients with synchronous MBC. Black bars; percentage including 
both groups. C: ROC curves were calculated to estimate the accuracy of the association of these markers in breast cancer 
diagnosis.
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of E-cadherin in most lobular carcinomas [36]. However,
we found E-cadherin expression in 95% of ductal carcino-
mas vs 61% for Nectin-4. E-cadherin is expressed in all
subtypes of ductal cancers, whereas Nectin-4 is only
expressed in a subset of ductal carcinomas that express
basal-like markers.
A major interest of Nectin-4 in breast cancer physiopa-
thology is that this protein is undetectable in normal
breast epithelium by IHC. Thus, Nectin-4 is a new tumor-
associated antigen and is a candidate for passive and
active immunotherapy. However we reproducibly
detected a low level of Nectin-4 mRNA in normal breast
epithelium (data not shown). This difference could theo-
retically be explained by i) a lack of sensibility of mAbs, ii)
a post-transcriptional regulation of Nectin-4 in normal
epithelia, iii) an active cleavage of transmembrane Nectin-
4 by TACE protease, iv) the expression of Nectin-4 in a dis-
crete population of cells within the mammary gland.
However, we found i) that our mAbs display a good sen-
sitivity in ELISA experiments (Fig. 4), ii) a good correla-
tion between Nectin-4 mRNA and protein level in breast
cancer cell lines (Fig. 1C), and iii) that the TACE protease
is weakly expressed in the normal mammary gland [28].
Since Nectin-4 expression clusters with basal markers, it is
conceivable that Nectin-4 could be present in a rare subset
of progenitor cells from which these tumors develop.
Nectin-4 as a serological marker for breast carcinomas
We and others have found a strong upregulation of TACE
protease active form in breast tumors [28,37]. We recently
deciphered the mechanism by which Nectin-4 is proc-
essed by TACE and showed that soluble Nectin-4 is
released as a 43.5 kDa form in both culture supernatant
and serum. Synthetic (TAPI-1) and natural (TIMP-3)
TACE inhibitors and RNA interference strongly affect Nec-
tin-4 cleavage [28]. TACE is thus mainly responsible for
Nectin-4 cleavage in breast tumors. TACE is involved in
numerous shedding processes both in normal and patho-
logical situations. The protease regulates MUC1 cleavage
and may contribute to the formation of CA15.3 marker.
Because there is no early marker for breast carcinoma, we
looked for the presence of soluble Nectin-4 in the serum
of patients with non-MBC. Unfortunately, serum Nectin-
4 failed to detect most patients with non-MBC and is thus
not a good marker of early breast cancer. Co-expression of
Nectin-4 and active TACE in a tumor may not be sufficient
to induce the release of detectable levels of Nectin-4 in the
serum of patients with non-MBC. A similar observation
could be done for CA15.3.
Serum Nectin-4 levels are often associated and vary con-
comitantly with CEA and CA15.3 levels in patients with
MBC. Interestingly, we noted that MUC1 is frequently
expressed with Nectin-4 in tumors, which could explain
the concomitant presence of both markers in patient sera
(data not shown). Frequent concomitant detection of
serum Nectin-4 with CEA and/or CA15.3 may suggest that
circulating Nectin-4 comes directly from tumor cells and
not from an indirect process such as immune response.
Serum Nectin-4 may complement CEA and CA15.3 detec-
tion. Nectin-4 can be detected in patients negative for
both markers or positive for only one marker and thus
Table 2: Correlation between serum Nectin-4, CA15.3, CEA with metastatic status.
Characteristics N° of patients (%) P-value
Nectin4 ≤ 30 (N = 51) 76.1% Nectin4 > 30 (N = 16) 23.9%
Multiple metastasis 20 (39) 11 (69) 0.038
Unique metastasis 31 (61) 5 (31)
Characteristics N° of patients (%) P-value
CA15.3 ≤ 50 (N = 30) 44.8% CA15.3 > 50 (N = 37) 55.2%
Multiple metastasis 10 (33) 21 (57) 0.056
Unique metastasis 20 (67) 16 (43)
Characteristics N° of patients (%) P-value
CEA ≤ 5 (N = 30) 44.8% CEA3 > 5 (N = 37) 55.2%
Multiple metastasis 12 (40) 19 (51) 0.354
Unique metastasis 18 (60) 18 (49)Page 12 of 16
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We showed that serum Nectin-4 is strongly associated
with metastatic progression (Fig. 5 and Table 2); this
could suggest a key role of this molecule during this proc-
ess. Finally, we showed that in addition to these proper-
ties, serum Nectin-4 is a marker of therapeutic efficiency
and could contribute to the improvement of patient fol-
low-up. Prospective analyses will evaluate the sensitivity
of this new marker, especially its ability to anticipate the
clinically observable recurrence.
We found that 50% of ovarian tumor cell lines express
transmembrane Nectin-4. Analysis of the sera of patients
with metastatic ovarian carcinoma revealed 1/25 positive
serum for Nectin-4 vs 19/25 for CA125 (data not shown).
We found 0/23 sera positive for Nectin-4 vs 18/23 for PSA
in patients with prostate carcinoma (data not shown).
Thus, serum Nectin-4 is not a valuable marker for ovarian
and prostate carcinomas. Similar observations were
reported for serum mammaglobin, where increased
serum levels are mainly detected in metastatic breast car-
cinomas [38].
Nectin-4 may be a new histological and serological
marker in breast carcinoma, but its function is unclear. We
previously identified Nectin-1 as the counter-receptor of
Nectin-4 [25]. Nectin-1 activation leads to the activation
of RAC and CDC42 which are involved in the formation
of lamellipodia and filopodia respectively. Nectin-4 could
promote migratory processes in breast cancer physiopa-
thology.
Conclusion
In this study, we investigated the potential role of Nectin-
4 as a new histological and serological tumor associated
marker for breast carcinomas. Nectin-4 and serum Nectin-
4 should serve as a new taxonomic, prognosis, and follow-
up marker for breast cancer.
Serum Nectin-4 and disease progressionFig re 5
Serum Nectin-4 and disease progression. Nectin-4, CEA and CA15.3 serum levels were determined during disease pro-
gression of a patient with a ductal carcinoma. The three markers were not detected at the time of diagnosis (white bar). Dur-
ing the progression of the disease, Nectin-4 serum levels increased to reach 402 pM. Grey, detection of pulmonary metastasis 
32 months post-diagnosis; black, detection of brain metastasis 39 months post-diagnosis. Ordinates represent pM for Nectin-4 
and International Units for CEA and CA15.3.
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Serum Nectin-4 and therapeutic efficiencyFig re 6
Serum Nectin-4 and therapeutic efficiency. Nectin-4, CEA and CA15.3 levels were determined in the serum of patients 
at the time of metastasis diagnosis and after therapy. Results are represented by arrows that symbolize increased, apparition, 
decreased, extinction, or unchanged ( ) levels of Nectin-4, CEA and CA15.3. Patient outcome was evalu-
ated according to clinical and histoclinical criteria.
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